The reason why the name IS important is because it all matters who the patient cohorts are that these centres are studying. If you don't have a defined group, the results will not mean anything. This has been a problem with previous studies. Which cohorts did they chose? Which definition of ME or CFS are they using? That is at the heart of what's important. If they study neuroimmune diseases, this could be a group of people that encompass ME, CFS, MS, Parkinsons etc.. How would the results be refined and usefull to us?